Skip to main content

Janssen's $2.5M Risperdal Verdict Appeal Declined

Janssen's $2.5M Risperdal Verdict Appeal Declined

Janssen's $2.5M Risperdal Verdict Appeal Declined

Introduction

Johnson & Johnson (J&J) and its subsidiaries, Janssen Pharmaceutical, appeal to reverse the $2.5 million gynecomastia verdict against its drug Risperdal has been turned down by the Pennsylvania Supreme Court.

The plaintiff from Alabama, now 20, started taking Risperdal for autism from the age of 8. He claimed the powerful antipsychotic drug was the reason for his gynecomastia, a condition characterized by the permanent development of female-like breasts in men and boys. Pennsylvania State Court jury awarded $2.5 million in compensatory damages in February 2015 to the plaintiff after finding that the defendants failed to warn about the side effects associated with the drug. The plaintiff was barred from seeking punitive damages as the defendants are headquartered in New Jersey, which prohibits punitive damages in product liability claims involving federally-approved medications.

J&J had raised an argument to overturn the verdict, which was rejected in October 2018, by the Pennsylvania Superior Court. Following the rejection, the defendants turned to the state Supreme Court hoping for a reversal. But on August 2nd, the justices refused to hear the case.

Around 7,000 gynecomastia lawsuits are pending in the Pennsylvania mass tort program. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775, presided by Honorable William Highberger) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Tepezza Hearing Loss MDL: Bellwether Trials Set for 2026

Categories: Tepezza

A U.S. District Judge overseeing Tepezza hearing damage lawsuits nationwide has scheduled four bellwether trials for 2026. These trials are intended to help both parties assess how juries may respond to the evidence and testimonies that could be…

3M Moves to Dismiss 100+ Bair Hugger Infection Lawsuits

Categories: Bair Hugger System

Nearly a decade after litigation first began, 3M Company continues to face thousands of lawsuits over its Bair Hugger warming blankets, which have been linked to…

Bayer May Issue New Stock to Fund Roundup Settlements

Categories: Roundup

Bayer has announced plans to issue new shares to finance legal settlements and ongoing litigation costs related to Roundup.
The company is also contemplating withdrawing its…

🎁 March VIP Medical Record Review Offer – Get 300 Pages Free!          
Includes a Free Life Care Plan Report + 10% Off Future Reviews!

Only 7 spots left out of 15—first come, first served!